Morgan Stanley Upgrades Centessa Pharmaceuticals (CNTA) to Overweight

Morgan Stanley analyst Jeff Hung upgraded Centessa Pharmaceuticals (NASDAQ: CNTA) from Equalweight to Overweight with a price target of $26.00 (from $11.00).

The analyst comments "Following interim ORX750 Phase 1 results, we see a clear path for Phase 2 development and believe orexin 2 is further derisked as a mechanism for treating narcolepsy. We upgrade our rating to Overweight (from Equal-weight) and raise our PT to $26 (from $11)."

For an analyst ratings summary and ratings history on Centessa Pharmaceuticals click here. For more ratings news on Centessa Pharmaceuticals click here.

Shares of Centessa Pharmaceuticals closed at $15.71 yesterday.

You May Also Be Interested In

• Beike (BEKE) PT Raised to $23 at Morgan Stanley
• Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer
• Kimbell Royalty closes $221.2M mineral rights acquisition